Prelude Therapeutics Inc - 10-Q Filing

Prelude Therapeutics reports Q3 2025 financial results including research and development expenses and updates on Incyte Corporation agreements.

SEC EDGAR ·

Tickers: $PRLD

Read the full article at SEC EDGAR

More Regulatory news